OYE Therapeutics

Invest in OYE - invest in the future 

OYE anticipates completing a near term clinical development and regulatory milestone upon receipt of the full readout of our Phase II human clinical study Q3/2022. 

Value Proposition

​"Open Your Eyes" is traditionally the first instruction you hear upon waking from general anesthesia following a medical procedure. OYE is making that safer for the patient and the medical professional. It's also our internal mandate to improve the patient experience through observation of the clinical process. Our mission is to save lives by filling gaps in care that have been overlooked.

Image of military personnel in the build

OYE ANNOUNCES SUCCESSFUL 

Pre-IND MEETING WITH THE FDA

CROWN POINT, INDIANA – O.Y.E. Therapeutics, a clinical stage pharmaceutical development company with a drug targeted at expediting emergence from anesthesia, has announced a successful Pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration.

A pre-IND meeting provides an opportunity for a drug development company and the FDA to discuss the IND development plan and to obtain the agency's guidance for clinical studies of the company's new drug candidate. 

“We are grateful for the guidance from the FDA as we move into our next phase of research. They were helpful as to what they wished to see regarding the safety profile of our product and offered feedback that our trial design would be effective at demonstrating efficacy in their eyes,” said O.Y.E. CEO Brett Dines. “They also articulated a path for development that is not at odds with our vision and desired timeline. It gives us more confidence in our approach to better clinical outcomes, enhanced patient safety, and an improved patient experience.”

DELAYED EMERGENCE FROM ANESTHESIA: Research shows delayed emergence results in billions of dollars in avoidable expense, millions of extra days in the hospital, and most urgently, 32,000 lives lost on an annual basis. The drug product from O.Y.E.’s lead clinical program helps patients emerge more quickly from anesthesia, especially following long and complicated surgical procedures or in patients who are more at risk (patients diagnosed with OSA - Obstructive Sleep Apnea, older patients, obese patients) for complications during this important clinical process at the end of a surgical case. 

O.Y.E. Therapeutics, Inc. is a clinical stage pharmaceutical development company with multiple therapy programs. The organization focuses on closing gaps in care pertaining to respiratory and cognitive support. Their solutions are aimed at some of the most pervasive and pressing issues in health care. Examples include: 

·  Improving procedural safety for an aging population driving an increased demand for surgery Improving procedural safety for an aging population driving an increased demand for surgery 

·  Strengthening emergent care related to the opioid crisis Strengthening emergent care related to the opioid crisis

·  Supporting rescue operations and the ability for self-preservation following traumatic injury Supporting rescue operations and the ability for self-preservation following traumatic injury

Image of military personnel in the build

Research agreement focuses
on battlefield injuries

OYE Therapeutics Inc., a Purdue University-affiliated company, is working to reduce the mortality and morbidity resulting from injuries on the battlefield through the development of new life-saving strategies.

OYE is located in the Purdue Technology Center in the Purdue Research Park of Northwest Indiana.

The company has entered into a Cooperative Research and Development Agreement (CRADA) with the Uniformed Services University of the Health Sciences (USU), an institution of higher learning within the U.S. Department of Defense and The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. (HJF).

The partnership includes researching the effectiveness of OYE-002 to enhance acute pain control at the point-of-injury, cognitive processing, psychomotor resilience and mission capabilities.

Read more at Purdue.edu